Imugene Initiates P-I (OASIS) Study for onCARlytics in Solid Tumor Patients
Shots:
- Imugene dosed the first patient of ovarian cancer in the P-I (OASIS) study evaluating onCARlytics (on-CAR-19, CF33-CD19 HOV4) in A/M 2L+ patients solid tumor (n=52) at City of Hope, California (US)
- OASIS is a dose escalation and dose expansion study assessing the safety & tolerability of onCARlytics (IV & IT) in combination with Blincyto vs monotherapy in solid tumor patients
- OnCARlytics is an innovative immunotherapy using CF33 oncolytic virus to deliver and present CD19 antigen on the cell wall of the solid tumor which in turn will help other CD19 drugs in this case Blincyto (bispecific CD19)
Ref: Imugene | Image: Imugene
Related News:- Imugene Entered into a Clinical Trial Supply Agreement with Roche to Evaluate PD1-Vaxx + Atezolizumab for the Treatment of Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
